Product Overview
Composition
pharmachologic effect
Indications
- non-suppurative forms of conjunctivitis, keratitis, keratoconjunctivitis without damage to the epithelium and blepharitis;
- scleritis and episcleritis;
- iritis, iridocyclitis and other uveitis of various origins;
- superficial damage to the cornea of ​​various etiologies (chemical, physical or immune mechanisms) after complete epithelialization of the cornea;
- inflammation of the posterior segment of the eye (choroiditis, chorioretinitis);
- sympathetic ophthalmia.
Allergic eye diseases:
- Allergic conjunctivitis or keratoconjunctivitis.
Prevention and treatment of inflammatory phenomena in the postoperative and post-traumatic period.
Application during pregnancy and lactation
Contraindications
- Keratitis associated with herpes simplex, chickenpox and other viral diseases of the cornea and conjunctiva.
- Tuberculosis of the eyes.
- Mycobacterial eye infections.
- Fungal eye infections.
- Acute purulent eye diseases.
- Damage to the corneal epithelium (including the state after removal of the corneal foreign body).
- Corneal epitheliopathy.
- Increased intraocular pressure.
- Glaucoma.
- Age up to 18 years (due to the lack of data on the efficacy and safety of the drug in children and adolescents under 18 years of age).
- Hypersensitivity to drug components.
Side effects
After instillation, a rapidly passing burning sensation, allergic reactions are possible.
With prolonged use it is possible
- the development of secondary glaucoma and steroid cataracts, as well as ulceration, opacity, thinning and / or perforation of the cornea;
- rarely - the spread of bacterial or herpes infections.
The preparation contains a preservative benzalkonium chloride, which may irritate the eyes.
Interaction
Interaction with other drugs is mainly due to participation in the elimination of dexamethasone isoenzyme CYP3A4. Dexamethasone induces the CYP3A4 isoenzyme, thus reducing the effectiveness of calcium channel blockers, quinidine and erythromycin. With the usual topical application, the dose of the drug is insufficient to induce the induction or saturation of liver enzymes.
With prolonged use with iodoxuridine, it is possible to enhance destructive processes in the corneal epithelium.
How to take, course of administration and dosage
In acute conditions
- 1-2 drops into the conjunctival sac every 1-2 hours.
After reducing inflammation
- 1-2 drops into the conjunctival sac 3-5 times / day.
The duration of treatment should not exceed 2-3 weeks.
The decision on the duration of treatment is based on objective data, including the effectiveness of the drug, the severity of clinical symptoms and the possible risk of side effects.
Overdose
Overdose with topical application of Oftan Dexamethasone eye drops is unlikely.
- Symptoms: Local irritation possible.
- Treatment: no specific antidote. The drug should be discontinued and symptomatic therapy should be prescribed.
Special instructions
If it is necessary to use contact lenses during treatment with Oftan Dexamethasone, they should be removed before using the drug and, if necessary, installed no earlier than 15 minutes after installation, because Oftan Dexamethasone contains the preservative benzalkonium chloride, which can be absorbed by soft contact lenses and cause discoloration and adverse effects on eye tissue.
If the treatment is more than 2 weeks, it is necessary to regularly monitor the intraocular pressure and the condition of the cornea.
Corticosteroid therapy can mask an ongoing bacterial or fungal infection. In the presence of infection, the use of drops should be combined with appropriate antimicrobial therapy.
Influence on the ability to drive vehicles and use mechanisms
In view of the possible lacrimation after instillation, the drug is not recommended to be used immediately before driving or operating mechanical equipment.
Release form
Eye drops in the form of a clear, colorless solution.
